Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

Published:2020-04-01 Issue:10 Volume:43 Page:1473-1483
ISSN:1720-8386
Container-title:Journal of Endocrinological Investigation
language:en
Short-container-title:J Endocrinol Invest

Author:

Bai X.,Chen X.,Wu X.,Huang Y.,Zhuang Y.,Chen Y.,Feng C.,Lin Xiahong^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s40618-020-01226-4.pdf

Reference33 articles.

1. Clarke JM, George DJ, Lisi S, Salama AKS (2018) Immune checkpoint blockade: the new frontier in Cancer treatment. Target Oncol 13:1–20. https://doi.org/10.1007/s11523-017-0549-7

2. Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J (2017) Immuno-oncology: the third paradigm in early drug development. Target Oncol 12:125–138. https://doi.org/10.1007/s11523-016-0471-4

3. Ruggeri RM, Campennì A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannavò S (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745–756. https://doi.org/10.1007/s40618-018-0984-z

4. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

5. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy: immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13:195–207. https://doi.org/10.1038/nrendo.2016.205

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine toxicity of cancer immunotherapy;International Journal of Molecular and Immuno Oncology;2024-08-31

2. Immune Checkpoint Inhibition;Side Effects of Cancer Therapy;2024

3. Managing adverse effects of novel immunotherapy in pancreatic cancer;Immune Landscape of Pancreatic Cancer Development and Drug Resistance;2024

4. Immune Checkpoint Inhibition;Side Effects of Cancer Therapy;2023-10-31

5. Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis;Journal of Cancer Research and Clinical Oncology;2023-08-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3